Baird served as co-manager on this offering
AboutSarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ-GS:SRPT) recently completed a follow-on offering of 4,107,286 shares of common stock, including the partial exercise of the over-allotment option. Sarepta sold 3,817,000 shares of common stock at a price to the public of $131.00 per share and the over-allotment was partially exercised for an additional 290,286 shares for total gross proceeds of $538 million.
Sarepta is a leader in precision genetic medicine for rare diseases, having built an impressive and competitive position in Duchenne muscular dystrophy and more recently in Limb-girdle muscular dystrophy, Charcot-Marie-Tooth and CNS-related disorders, reaching over 20 therapies in various stages of development. The Company’s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. Sarepta is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
- November 2018
- Sarepta Therapeutics, Inc.
- Target Location
- North America